Skip to main content
Clinical Trials/CTRI/2022/08/044783
CTRI/2022/08/044783
Completed
Phase 2

EVALUATION OF EFFICACY AND SAFETY OF TOPICAL OXYMETAZOLINE 0.1% IN TREATMENT OF ACQUIRED PTOSIS

DR RPCENTRE FOR OPHTHALMIC SCIENCES0 sites20 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: H024- Ptosis of eyelid
Sponsor
DR RPCENTRE FOR OPHTHALMIC SCIENCES
Enrollment
20
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
October 10, 2023
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
DR RPCENTRE FOR OPHTHALMIC SCIENCES

Eligibility Criteria

Inclusion Criteria

  • 1\.PATIENT WITH ACQUIRED PTOSIS
  • 2\.PATIENT WITHOUT HISTORY OF PTOSIS CORRECTION
  • 3\.PATIENT OR PARENTS WILLING TO GIVE CONSENT

Exclusion Criteria

  • 1\.PATIENTS DIAGNOSED AS CONGENITAL PTOSIS
  • 2\.PATIENTS WITH HORNER SYNDROME
  • 3\.PATIENTS WITH MYASTHENIA GRAVIS
  • 4\.PATIENTS HAVING MECHANICAL PTOSIS
  • 5\.PATIENTS WITH PSEUDOPTOSIS
  • 6\.PATIENTS WITH CEREBRAL OR CORONARY INSUFFICIENCY
  • 7\.SJOGREN SYNDROME PATIENTS
  • 8\.HYPERTENSIVE PATIENTS
  • 9\.GLAUCOMA PATIENTS
  • 10\.PATIENTS ON BETA BLOCKERS

Outcomes

Primary Outcomes

Not specified

Similar Trials